The Patent Lawyer - Logo
Rotating Image Link
Published November 16, 2026

Bayer Intellectual Property GmbH obtained patent No. 2297415 in 2000 for Rivaroxaban, a medicine used to treat venous thromboembolism. The patent was valid until 2024. It protected the active substance Rivaroxaban, corresponding pharmaceutical substances, and drugs containing Rivaroxaban under the trade name Xarelto.

At the end of its term, the patent owner discovered infringement and sued Promomed Rus Ltd. (Respondent 1), Biokhimik JSC (Respondent 2), and Biopreparat JSC (Respondent 3) (Case No. А40-187991/24-12-1574) for the unlawful use of the patented medicine. Bayer sought compensation of more than RUB 12 million.

Bayer argued that the Russian companies had used the patented medicine from June 2024 to December 2024, i.e., until the end of the patent’s term of validity.

The patent’s expiration did not prevent the smooth conduct of the judicial proceedings.

Bayer learned that Respondent 1 had registered Rivaroxaban in the state register in January 2024. The drug was produced by Respondent 2. In fact, this was a drug reproducing the original drug Xarelto.

When Bayer became aware, it sent warning letters to Respondent 1 and Respondent 2 in April 2024. Bayer asked the respondents to delay marketing the drug until the patent expired. The respondents ignored Bayer’s warning letters. On the contrary, Respondent 2 began selling the drug in June 2024.

In addition, Respondent 3 concluded contracts with a regional ministry of health providing for the sale of the drug for more than RUB 3 million, also with another regional ministry of health for almost RUB 20 million, with a company from the Moscow region for more than RUB 22 million, and with a company from the Volgograd region for more than RUB 4 million.

Thus, Respondents 1 and 2 jointly registered and marketed the reproduced Rivaroxaban medicine despite receiving warning letters from Bayer. In turn, Respondent 3 was selling the drug to medical institutions.

The court partially satisfied the claims after examining the totality of the submitted evidence. The court stated that Bayer owned patent No. 2836548 from December 11, 2000, to December 4, 2024. Furthermore, patent No. 2297415 was partially invalidated, after which the patent office issued a new patent No. 2836548 with amended claims. The grant of a new patent No. 2836548 with amended claims, instead of the partial invalidation of patent No. 2297415, did not rule out infringement of patent No. 2836548.

To confirm infringement, the court ordered an expert report to confirm that patent No. 2836548 protected the same substance as the unlawfully reproduced Rivaroxaban.

The expert report confirmed unlawful use of the patent, with the amended claims, in the reproduced drug Rivaroxaban. The court also confirmed the sales of the reproduced drug.

The court ruled in favor of Bayer, holding that the use of the drug by Respondents 1, 2, and 3 was unlawful; therefore, the plaintiff may, at his choice, demand payment of compensation instead of damages, or payment of compensation at double the cost of use of the invention under comparable circumstances. The required compensation should be paid jointly by Respondents 1 and 2. Respondent 3 was ordered to pay for the expert report and pay the government fee.

The court is competent to reduce the compensation amount depending on the particular circumstances of the case, such as the nature of the infringement, whether it was the first infringement, or whether other circumstances allow a reduction in the amount of compensation. The court heard the respondents’ arguments and concluded that it was reasonable and commensurate to award the plaintiff compensation of about RUB 3.5 million. i.e., the cost of the medicine. The judgment was handed down on August 12, 2026, almost two years after the patent term expired. It is never too late to assert one’s rights.

Vladimir Biriulin

Written by Vladimir Biriulin

Gorodissky & Partners

You may also like…

Contact us to write for out Newsletter

The Patent Lawyer - Logo

Subscribe To Our Newsletter

Would you like to receive our popular weekly news alerts straight to your inbox? Solely patent focused and only sent once a week means you can guarantee there will be something you are interested in reading instead of clogging up your inbox with junk. Sign up now!

You have Successfully Subscribed!